Compare Stocks → The Next Step of Their Control Is Here … (From Weiss Ratings) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:AYLANASDAQ:FENCNASDAQ:GNFTNASDAQ:INMB Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAYLAAyala Pharmaceuticals$0.50$0.48$0.36▼$7.31$7.46M1.9876,300 shsN/AFENCFennec Pharmaceuticals$9.21+0.5%$10.05$6.30▼$11.92$249.59M0.38115,585 shs154,291 shsGNFTGenfit$3.49+1.2%$3.58$2.89▼$4.75$173.91M1.0814,712 shs1,426 shsINMBINmune Bio$11.29+4.2%$11.40$6.50▼$14.74$205.48M1.9996,746 shs77,738 shsThe 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAYLAAyala Pharmaceuticals0.00%0.00%0.00%0.00%0.00%FENCFennec Pharmaceuticals+0.99%-4.28%-15.89%-7.47%+12.25%GNFTGenfit+0.15%0.00%-1.99%-9.92%-6.76%INMBINmune Bio+2.07%+23.18%-8.75%-10.26%+55.30%Move Your Money Before May 22 (Ad)The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AFENCFennec Pharmaceuticals2.7466 of 5 stars3.50.00.00.03.12.51.9GNFTGenfit0.6785 of 5 stars3.52.00.00.00.60.00.0INMBINmune Bio1.4784 of 5 stars3.51.00.00.03.11.70.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAYLAAyala PharmaceuticalsN/AN/AN/AN/AFENCFennec Pharmaceuticals3.00Buy$17.3388.20% UpsideGNFTGenfit3.00Buy$11.00215.19% UpsideINMBINmune Bio3.00Buy$16.0041.72% UpsideCurrent Analyst RatingsLatest FENC, AYLA, GNFT, and INMB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/5/2024GNFTGenfitHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.004/4/2024FENCFennec PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$17.00 ➝ $18.003/18/2024FENCFennec PharmaceuticalsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$16.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAYLAAyala Pharmaceuticals$3.51M2.13N/AN/A$2.45 per share0.21FENCFennec Pharmaceuticals$21.25M11.75N/AN/A($0.43) per share-21.42GNFTGenfit$41.31M4.21N/AN/A$1.48 per share2.36INMBINmune Bio$160K1,284.24N/AN/A$2.07 per share5.45Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAYLAAyala Pharmaceuticals-$40.25M-$2.52N/AN/AN/A-2,341.69%-182.13%-139.83%N/AFENCFennec Pharmaceuticals-$16.05M-$0.61N/A13.16N/A-75.50%N/A-73.64%5/9/2024 (Estimated)GNFTGenfit-$31.27MN/A0.00N/AN/AN/AN/AN/A7/4/2024 (Estimated)INMBINmune Bio-$30.01M-$1.67N/A∞N/A-19,360.00%-64.11%-45.57%5/1/2024 (Estimated)Latest FENC, AYLA, GNFT, and INMB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023INMBINmune BioN/A-$0.47-$0.47-$0.47N/A$0.03 million3/21/2024Q4 2023FENCFennec Pharmaceuticals$0.02-$0.10-$0.12-$0.10$9.47 million$9.74 millionDividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAYLAAyala PharmaceuticalsN/AN/AN/AN/AN/AFENCFennec PharmaceuticalsN/AN/AN/AN/AN/AGNFTGenfitN/AN/AN/AN/AN/AINMBINmune BioN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAYLAAyala PharmaceuticalsN/A2.282.28FENCFennec PharmaceuticalsN/A3.563.27GNFTGenfit0.922.942.94INMBINmune BioN/A2.162.16OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAYLAAyala Pharmaceuticals22.10%FENCFennec Pharmaceuticals55.51%GNFTGenfit2.24%INMBINmune Bio12.72%Insider OwnershipCompanyInsider OwnershipAYLAAyala Pharmaceuticals3.60%FENCFennec Pharmaceuticals11.25%GNFTGenfit4.20%INMBINmune Bio36.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAYLAAyala Pharmaceuticals3514.82 million14.29 millionNot OptionableFENCFennec PharmaceuticalsN/A27.10 million24.05 millionOptionableGNFTGenfit15949.83 million47.74 millionNot OptionableINMBINmune Bio1118.20 million11.63 millionOptionableFENC, AYLA, GNFT, and INMB HeadlinesSourceHeadlineINmune Bio Independent Director Acquires 80% More Stockfinance.yahoo.com - April 26 at 8:32 AMInmune Bio Earns Buy Rating on Positive XPro Developments and Strong Financialsmarkets.businessinsider.com - April 25 at 9:09 PMINmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rulesglobenewswire.com - April 25 at 9:00 AMINmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity Assayglobenewswire.com - April 23 at 8:00 AMINmune Bio rises 2%, on $4.5M direct offeringmsn.com - April 22 at 3:42 PMINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offeringfinance.yahoo.com - April 22 at 10:41 AMINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the Offeringglobenewswire.com - April 22 at 8:00 AMINmune Bio, Inc. (NASDAQ:INMB) Sees Large Increase in Short Interestamericanbankingnews.com - April 16 at 5:34 AMINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024finance.yahoo.com - April 8 at 8:33 AMINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024globenewswire.com - April 8 at 8:00 AMAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)markets.businessinsider.com - April 2 at 11:32 PMINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 1 at 12:16 PMINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lagsfinance.yahoo.com - March 31 at 10:18 AMINmune Bio, Inc. (INMB) Q4 2023 Earnings Call Transcriptseekingalpha.com - March 30 at 2:42 PMINmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical Advancementsfinance.yahoo.com - March 29 at 7:30 PMINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Updatefinanznachrichten.de - March 29 at 9:29 AMINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business Updateglobenewswire.com - March 28 at 4:01 PMINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28globenewswire.com - March 26 at 4:01 PMINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene Therapyglobenewswire.com - March 13 at 8:00 AMINmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XProfinanznachrichten.de - March 6 at 7:23 PMBuy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment Developmentsmarkets.businessinsider.com - March 6 at 7:23 PMINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™globenewswire.com - March 5 at 8:00 AMINMB Jun 2024 25.000 callfinance.yahoo.com - February 17 at 10:36 PMINMB Mar 2024 20.000 callfinance.yahoo.com - February 16 at 9:33 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:AYLAAyala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.Fennec PharmaceuticalsNASDAQ:FENCFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.GenfitNASDAQ:GNFTGenfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.INmune BioNASDAQ:INMBINmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03 develop pre-clinical data in cancer that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.